Xeris Pharmaceuticals | XERS - Pre Tax Profit


Xeris Pharmaceuticals reported $2.23M in Pre-Tax Profit for its fiscal quarter ending in March of 2026.





Pre Tax Profit Change Date
Celltrion KRW 11.84B 1.34B Mar/2026
Cspc Pharmaceutical CNY 505.59M 706M Dec/2025
Dianthus Therapeutics USD -40.83M 23.6M Mar/2026
Divis Laboratories Ltd INR 9.63B 1.09B Mar/2026
Eli Lilly USD 8.27B 1.03B Dec/2025
Kangmei Pharma CNY -14.01M 16.08M Mar/2026
Knight Therapeutics CAD -1.92M 13.69M Sep/2025
Laboratorios Farma EUR 26.78M 94.77M Jun/2025
Medical Developments International AUD -149K 466K Jun/2025
Nektar Therapeutics USD -34.7M 2.35M Dec/2025
Neuren Pharmaceuticals AUD 9.86M 161.24M Jun/2025
Organigram Holdings CAD -921K 40.8M Mar/2026
Pacira USD 571K 8.95M Dec/2025
Perrigo USD -1.33B 1.35B Dec/2025
Pharma Mar EUR 1.6M 38.6M Mar/2026
Qiagen NV USD 109.17M 25.56M Dec/2025
Sartorius EUR 157.8M 76.1M Mar/2026
Supernus Pharmaceuticals USD -5.95M 4.04M Mar/2026
Tilray USD -39.96M 39.19M Sep/2025
Zealand Pharma A/S -406.5M 39.77M Dec/2025
Zz Pientze Pharmaceu CNY 876.07M 352.96M Mar/2026